682 related articles for article (PubMed ID: 22023098)
1. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
J Med Econ; 2011; 14(6):824-34. PubMed ID: 22023098
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.
Diamantopoulos A; Lees M; Wells PS; Forster F; Ananthapavan J; McDonald H
Thromb Haemost; 2010 Oct; 104(4):760-70. PubMed ID: 20806107
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.
Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
Pharmacoeconomics; 2012 Feb; 30(2):87-101. PubMed ID: 22187932
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective.
McDonald H; Diamantopoulos A; Wells P; Lees M; Folkerts K; Forster F; Ananthapavan J
J Med Econ; 2012; 15(5):817-28. PubMed ID: 22494267
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.
Kwong LM
Am J Manag Care; 2011 Feb; 17(1 Suppl):S22-6. PubMed ID: 21517652
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.
Duggan ST
Am J Cardiovasc Drugs; 2012 Feb; 12(1):57-72. PubMed ID: 22272729
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
Monreal M; Folkerts K; Diamantopoulos A; Imberti D; Brosa M
Thromb Haemost; 2013 Nov; 110(5):987-94. PubMed ID: 23965805
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden.
Ryttberg L; Diamantopoulos A; Forster F; Lees M; Fraschke A; Björholt I
Expert Rev Pharmacoecon Outcomes Res; 2011 Oct; 11(5):601-15. PubMed ID: 21958104
[TBL] [Abstract][Full Text] [Related]
10. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
McCullagh L; Tilson L; Walsh C; Barry M
Pharmacoeconomics; 2009; 27(10):829-46. PubMed ID: 19803538
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies.
Turpie AG; Lassen MR; Eriksson BI; Gent M; Berkowitz SD; Misselwitz F; Bandel TJ; Homering M; Westermeier T; Kakkar AK
Thromb Haemost; 2011 Mar; 105(3):444-53. PubMed ID: 21136019
[TBL] [Abstract][Full Text] [Related]
12. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery.
Van Thiel D; Kalodiki E; Wahi R; Litinas E; Haque W; Rao G
Clin Appl Thromb Hemost; 2009; 15(4):389-94. PubMed ID: 19608550
[TBL] [Abstract][Full Text] [Related]
13. [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
Gómez Arrayas I; Suárez Fernández C; Gómez Cerezo JF; Betegón Nicolás L; de Salas-Cansado M; Rubio-Terrés C
Rev Esp Salud Publica; 2012 Dec; 86(6):601-12. PubMed ID: 23325135
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.
Wolowacz SE; Roskell NS; Maciver F; Beard SM; Robinson PA; Plumb JM; Dolan G; Brenkel IJ
Clin Ther; 2009 Jan; 31(1):194-212. PubMed ID: 19243718
[TBL] [Abstract][Full Text] [Related]
15. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
16. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Nieto JA; Espada NG; Merino RG; González TC
Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
[TBL] [Abstract][Full Text] [Related]
17. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Huisman MV; Quinlan DJ; Dahl OE; Schulman S
Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
[TBL] [Abstract][Full Text] [Related]
18. An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.
Lereun C; Wells P; Diamantopoulos A; Rasul F; Lees M; Sengupta N
J Med Econ; 2011; 14(2):238-44. PubMed ID: 21385145
[TBL] [Abstract][Full Text] [Related]
19. A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting.
Zindel S; Stock S; Müller D; Stollenwerk B
BMC Health Serv Res; 2012 Jul; 12():192. PubMed ID: 22776616
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain.
Gómez-Outes A; Avendaño-Solá C; Terleira-Fernández AI; Vargas-Castrillón E
Pharmacoeconomics; 2014 Sep; 32(9):919-36. PubMed ID: 24895235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]